InnoCare Pharma Limited (HKG:9969)

InnoCare Pharma Statistics

Total Valuation

InnoCare Pharma has a market cap or net worth of HKD 34.40 billion. The enterprise value is 28.37 billion.

Market Cap	34.40B
Enterprise Value	28.37B

Important Dates

The next estimated earnings date is Monday, November 10, 2025.

Earnings Date	Nov 10, 2025
Ex-Dividend Date	n/a

Share Statistics

InnoCare Pharma has 1.76 billion shares outstanding. The number of shares has decreased by -3.05% in one year.

Current Share Class	1.49B
Shares Outstanding	1.76B
Shares Change (YoY)	-3.05%
Shares Change (QoQ)	-32.52%
Owned by Insiders (%)	20.88%
Owned by Institutions (%)	40.26%
Float	1.39B

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	23.76
PB Ratio	4.67
P/TBV Ratio	4.87
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-123.93
EV / Sales	19.59
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-134.22

Financial Position

The company has a current ratio of 7.66, with a Debt / Equity ratio of 0.23.

Current Ratio	7.66
Quick Ratio	7.27
Debt / Equity	0.23
Debt / EBITDA	n/a
Debt / FCF	-7.98
Interest Coverage	-7.49

Financial Efficiency

Return on equity (ROE) is -3.23% and return on invested capital (ROIC) is -2.80%.

Return on Equity (ROE)	-3.23%
Return on Assets (ROA)	-2.48%
Return on Invested Capital (ROIC)	-2.80%
Return on Capital Employed (ROCE)	-4.54%
Revenue Per Employee	1.23M
Profits Per Employee	-194,635
Employee Count	939
Asset Turnover	0.14
Inventory Turnover	1.31

Taxes

In the past 12 months, InnoCare Pharma has paid 5.80 million in taxes.

Income Tax	5.80M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +225.00% in the last 52 weeks. The beta is 0.98, so InnoCare Pharma's price volatility has been similar to the market average.

Beta (5Y)	0.98
52-Week Price Change	+225.00%
50-Day Moving Average	17.90
200-Day Moving Average	11.41
Relative Strength Index (RSI)	50.57
Average Volume (20 Days)	19,082,454

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, InnoCare Pharma had revenue of HKD 1.45 billion and -228.89 million in losses. Loss per share was -0.14.

Revenue	1.45B
Gross Profit	1.28B
Operating Income	-414.63M
Pretax Income	-235.87M
Net Income	-228.89M
EBITDA	-333.22M
EBIT	-414.63M
Loss Per Share	-0.14

Balance Sheet

The company has 7.73 billion in cash and 1.69 billion in debt, giving a net cash position of 6.05 billion or 3.43 per share.

Cash & Cash Equivalents	7.73B
Total Debt	1.69B
Net Cash	6.05B
Net Cash Per Share	3.43
Equity (Book Value)	7.36B
Book Value Per Share	6.06
Working Capital	7.47B

Cash Flow

In the last 12 months, operating cash flow was -158.71 million and capital expenditures -52.62 million, giving a free cash flow of -211.33 million.

Operating Cash Flow	-158.71M
Capital Expenditures	-52.62M
Free Cash Flow	-211.33M
FCF Per Share	-0.12

Margins

Gross margin is 88.27%, with operating and profit margins of -28.64% and -15.81%.

Gross Margin	88.27%
Operating Margin	-28.64%
Pretax Margin	-16.29%
Profit Margin	-15.81%
EBITDA Margin	-23.02%
EBIT Margin	-28.64%
FCF Margin	n/a

Dividends & Yields

InnoCare Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	3.05%
Shareholder Yield	n/a
Earnings Yield	-0.67%
FCF Yield	-0.61%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

InnoCare Pharma has an Altman Z-Score of 3.26 and a Piotroski F-Score of 4.

Altman Z-Score	3.26
Piotroski F-Score	4